NCT02255175View on ClinicalTrials.gov

Perimenopausal Effects of Estradiol on Reward Responsiveness

PHASE4CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 1, 2015

Primary Completion Date

October 17, 2018

Study Completion Date

October 17, 2018

Conditions
Perimenopausal Depression
Interventions
DRUG

Estradiol

Participants will receive transdermal estradiol (100μg/day) for 3 weeks

DRUG

Progesterone

Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.

Trial Locations (1)

27514

University of North Carolina, Chapel Hill

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT02255175 - Perimenopausal Effects of Estradiol on Reward Responsiveness | Biotech Hunter | Biotech Hunter